By Andrew MacAskill and Maggie Fick BEIJING/LONDON, Jan 29 (Reuters) - UK drugmaker AstraZeneca will invest $15 billion in ...

Whether in China or the United States, AstraZeneca's chief exec Pascal Soriot (pictured) knows how to capture headlines.

AstraZeneca made a big commitment to China as CEO Pascal Soriot joined British Prime Minister Keir Starmer on a trip to the ...

AstraZeneca PLC (NASDAQ:AZN) is one of the stocks Jim Cramer shed light on recently. When a caller mentioned that they are ...

AstraZeneca's decision to invest more than 100 billion yuan ($14.39 billion) in China by 2030 marks a new chapter for the British drug-maker in a market it increasingly sees as central to global ...

AstraZeneca announces a $15B China investment through 2030 to expand manufacturing and R&D in cell therapy and radioconjugates—read the full update now.

British pharmaceutical group AstraZeneca said Thursday that it would invest $15 billion in China through 2030 to expand its ...

AstraZeneca has announced a $15 billion investment in China through 2030 to expand medicines manufacturing and R&D.

On Saturday, 31 January, the China-Britain Business Council (CBBC) and the British Chamber of Commerce Shanghai (BritCham ...

AstraZeneca announced on Thursday that it plans to invest more than 100 billion yuan ($15 billion) in China by 2030 to expand its pharmaceutical manufacturing and research and development footprint.

Pascal Soriot, CEO, AZ, hailed the investment as the start of "an exciting next chapter" for the company in China.